These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 24129809)
1. Impact of adding cisplatin to S-1 in elderly patients with advanced gastric cancer. Terazawa T; Iwasa S; Takashima A; Nishitani H; Honma Y; Kato K; Hamaguchi T; Yamada Y; Shimada Y J Cancer Res Clin Oncol; 2013 Dec; 139(12):2111-6. PubMed ID: 24129809 [TBL] [Abstract][Full Text] [Related]
2. A phase II study of combination therapy with oral S-1 and cisplatin in elderly patients with advanced gastric cancer. Sasaki Y; Iwasa S; Okazaki S; Goto M; Kojima Y; Naganuma A; Nagashima K; Nagai Y; Hirano H; Honma Y; Takashima A; Kato K; Hamaguchi T Gastric Cancer; 2018 May; 21(3):439-445. PubMed ID: 28766263 [TBL] [Abstract][Full Text] [Related]
3. A randomised phase II trial of capecitabine plus cisplatin versus S-1 plus cisplatin as a first-line treatment for advanced gastric cancer: Capecitabine plus cisplatin ascertainment versus S-1 plus cisplatin randomised PII trial (XParTS II). Nishikawa K; Tsuburaya A; Yoshikawa T; Kobayashi M; Kawada J; Fukushima R; Matsui T; Tanabe K; Yamaguchi K; Yoshino S; Takahashi M; Hirabayashi N; Sato S; Nemoto H; Rino Y; Nakajima J; Aoyama T; Miyagi Y; Oriuchi N; Yamaguchi K; Miyashita Y; Morita S; Sakamoto J Eur J Cancer; 2018 Sep; 101():220-228. PubMed ID: 30096702 [TBL] [Abstract][Full Text] [Related]
4. Phase II study of cetuximab plus S-1/cisplatin therapy in Japanese patients with advanced gastric cancer. Yamaguchi K; Fuse N; Komatsu Y; Fujii H; Hironaka S; Omuro Y; Muro K; Yasui H; Ueda S; Nishina T; Watanabe M; Ohtsu A Jpn J Clin Oncol; 2021 May; 51(6):879-885. PubMed ID: 33561262 [TBL] [Abstract][Full Text] [Related]
5. Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study. Ajani JA; Buyse M; Lichinitser M; Gorbunova V; Bodoky G; Douillard JY; Cascinu S; Heinemann V; Zaucha R; Carrato A; Ferry D; Moiseyenko V Eur J Cancer; 2013 Nov; 49(17):3616-24. PubMed ID: 23899532 [TBL] [Abstract][Full Text] [Related]
6. Comparison of safety and efficacy of S-1 monotherapy and S-1 plus cisplatin therapy in elderly patients with advanced gastric cancer. Tsushima T; Hironaka S; Boku N; Machida N; Yamazaki K; Yasui H; Fukutomi A; Todaka A; Taniguchi H; Onozawa Y; Taku K Int J Clin Oncol; 2013 Feb; 18(1):10-6. PubMed ID: 22020563 [TBL] [Abstract][Full Text] [Related]
7. S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin as first-line therapy in patients with advanced gastric cancer (SOLAR): a randomised, open-label, phase 3 trial. Kang YK; Chin K; Chung HC; Kadowaki S; Oh SC; Nakayama N; Lee KW; Hara H; Chung IJ; Tsuda M; Park SH; Hosaka H; Hironaka S; Miyata Y; Ryu MH; Baba H; Hyodo I; Bang YJ; Boku N Lancet Oncol; 2020 Aug; 21(8):1045-1056. PubMed ID: 32682457 [TBL] [Abstract][Full Text] [Related]
8. Five-weekly S-1 plus cisplatin therapy combined with trastuzumab therapy in HER2-positive gastric cancer: a phase II trial and biomarker study (WJOG7212G). Miura Y; Sukawa Y; Hironaka S; Mori M; Nishikawa K; Tokunaga S; Okuda H; Sakamoto T; Taku K; Nishikawa K; Moriwaki T; Negoro Y; Kimura Y; Uchino K; Shinozaki K; Shinozaki H; Musha N; Yoshiyama H; Tsuda T; Miyata Y; Sugimoto N; Shirakawa T; Ito M; Yonesaka K; Yoshimura K; Boku N; Nosho K; Takano T; Hyodo I Gastric Cancer; 2018 Jan; 21(1):84-95. PubMed ID: 28497176 [TBL] [Abstract][Full Text] [Related]
9. S-1 plus cisplatin versus fluorouracil plus cisplatin in advanced gastric or gastro-esophageal junction adenocarcinoma patients: a pilot study. Li YH; Qiu MZ; Xu JM; Sun GP; Lu HS; Liu YP; Zhong MZ; Zhang HL; Yu SY; Li W; Hu XH; Wang JJ; Cheng Y; Zhou JT; Guo ZQ; Guan ZG; Xu RH Oncotarget; 2015 Oct; 6(33):35107-15. PubMed ID: 26439700 [TBL] [Abstract][Full Text] [Related]
10. Preoperative chemotherapy with S-1 and cisplatin for highly advanced gastric cancer. Nashimoto A; Yabusaki H; Nakagawa S; Takii Y; Tsuchiya Y; Otsuo T Anticancer Res; 2009 Nov; 29(11):4689-96. PubMed ID: 20032421 [TBL] [Abstract][Full Text] [Related]
11. Three-weekly S-1 plus cisplatin chemotherapy as first-line treatment for advanced gastric cancer. Choi IS; Lee KW; Kim KH; Kim YJ; Kim JH; Lee JS Med Oncol; 2010 Sep; 27(3):992-7. PubMed ID: 20077040 [TBL] [Abstract][Full Text] [Related]
12. [A safety analysis in patients treated with oxaliplatin plus S-1 as adjuvant therapy for gastric cancer]. Zhou Y; Huang J; Yang L; Chi Y; Qu T; Lü X; Wang JW Zhonghua Zhong Liu Za Zhi; 2012 Nov; 34(11):860-4. PubMed ID: 23291138 [TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant chemotherapy with S-1 and CDDP in advanced gastric cancer. Kochi M; Fujii M; Kanamori N; Kaiga T; Takahashi T; Kobayashi M; Takayama T J Cancer Res Clin Oncol; 2006 Dec; 132(12):781-5. PubMed ID: 16804723 [TBL] [Abstract][Full Text] [Related]
14. Multicenter phase II study of trastuzumab plus S-1 alone in elderly patients with HER2-positive advanced gastric cancer (JACCRO GC-06). Kimura Y; Fujii M; Masuishi T; Nishikawa K; Kunisaki C; Matsusaka S; Segawa Y; Nakamura M; Sasaki K; Nagao N; Hatachi Y; Yuasa Y; Asami S; Takeuchi M; Furukawa H; Nakajima T; Gastric Cancer; 2018 May; 21(3):421-427. PubMed ID: 28936560 [TBL] [Abstract][Full Text] [Related]
15. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Koizumi W; Narahara H; Hara T; Takagane A; Akiya T; Takagi M; Miyashita K; Nishizaki T; Kobayashi O; Takiyama W; Toh Y; Nagaie T; Takagi S; Yamamura Y; Yanaoka K; Orita H; Takeuchi M Lancet Oncol; 2008 Mar; 9(3):215-21. PubMed ID: 18282805 [TBL] [Abstract][Full Text] [Related]
16. First-line chemotherapy with S-1 alone or S-1 plus cisplatin for elderly patients with advanced gastric cancer: a multicenter propensity score matched study. Makiyama A; Kunieda K; Noguchi M; Kajiwara T; Tamura T; Takeda K; Sugiyama J; Minashi K; Moriwaki T; Sugimoto N; Nagase M; Negoro Y; Tsuda T; Shimodaira H; Okano N; Tsuji A; Sakai D; Yanagihara K; Ueda S; Tamura S; Otsu S; Honda T; Matsushita Y; Okuno T; Kashiwada T; Nozaki A; Ebi M; Okuda H; Shimokawa M; Hironaka S; Hyodo I; Baba E; Boku N; Muro K; Esaki T Gastric Cancer; 2018 Sep; 21(5):792-801. PubMed ID: 29353332 [TBL] [Abstract][Full Text] [Related]
17. S-1 Based Doublet as an Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer: Results from the Randomized Phase III POST Trial. Lee CK; Jung M; Kim HS; Jung I; Shin DB; Kang SY; Zang DY; Kim KH; Lee MH; Kim BS; Lee KH; Cheong JH; Hyung WJ; Noh SH; Chung HC; Rha SY Cancer Res Treat; 2019 Jan; 51(1):1-11. PubMed ID: 29397659 [TBL] [Abstract][Full Text] [Related]
18. A phase III trial comparing oral S-1/cisplatin and intravenous 5-fluorouracil/cisplatin in patients with untreated diffuse gastric cancer. Ajani JA; Abramov M; Bondarenko I; Shparyk Y; Gorbunova V; Hontsa A; Otchenash N; Alsina M; Lazarev S; Feliu J; Elme A; Esko V; Abdalla K; Verma U; Benedetti F; Aoyama T; Mizuguchi H; Makris L; Rosati G; Ann Oncol; 2017 Sep; 28(9):2142-2148. PubMed ID: 28911091 [TBL] [Abstract][Full Text] [Related]
19. Impacts of fluorouracil-metabolizing enzymes on the outcomes of patients treated with S-1 alone or S-1 plus cisplatin for first-line treatment of advanced gastric cancer. Koizumi W; Tanabe S; Azuma M; Ishido K; Nishimura K; Sasaki T; Nakatani K; Higuchi K; Nakayama N; Katada C Int J Cancer; 2010 Jan; 126(1):162-70. PubMed ID: 19588501 [TBL] [Abstract][Full Text] [Related]
20. [Safety and effectiveness of oxaliplatin combined with capecitabine or oxaliplatin combined with S-1 neoadjuvant chemotherapy in the treatment of advanced gastric cancer]. Xie BW; Zang L; Ma JJ; Sun J; Yang X; Wang ML; Lu AG; Hu WG; Zheng MH Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):138-144. PubMed ID: 33508919 [No Abstract] [Full Text] [Related] [Next] [New Search]